COPD for USMLE Step 1
Start your One-Week Free Trial
Already subscribed? Log in »
Chronic obstructive pulmonary disease for the USMLE Step 1 Exam
Pathophysiology
- Chronic Inflammation:
- COPD is characterized by chronic inflammation of the airways and lung parenchyma.
- Exposure to irritants (e.g., cigarette smoke) leads to the recruitment of neutrophils, macrophages, and CD8+ T cells, resulting in tissue damage.
- Airflow Limitation:
- Airflow obstruction in COPD is due to:
- Small airway disease (bronchiolitis): Inflammation and narrowing of the small bronchioles.
- Emphysema: Destruction of alveolar walls, leading to loss of elastic recoil and air trapping.
- Protease-Antiprotease Imbalance:
- Proteases (e.g., neutrophil elastase) break down lung tissue, while antiproteases (e.g., alpha-1 antitrypsin) protect it.
- In COPD, an increase in protease activity, often exacerbated by smoking, leads to tissue destruction.
- Oxidative Stress:
- Oxidants from smoking and inflammatory cells contribute to lung damage by amplifying inflammation and inactivating protective antiproteases.
Risk Factors
- Smoking:
- The primary cause of COPD, with a direct relationship between pack-years of smoking and disease risk.
- Environmental Exposure:
- Chronic exposure to air pollutants and occupational hazards (e.g., dust, chemicals) increases COPD risk.
- Genetics:
- Alpha-1 antitrypsin deficiency is a genetic cause of COPD, particularly associated with early-onset emphysema.
Clinical Features
- Chronic Cough and Sputum Production:
- Often the earliest symptoms, typically worse in the morning and accompanied by mucous expectoration.
- Dyspnea:
- Progressive breathlessness, particularly during physical activity, is a key feature of COPD.
- Wheezing:
- Wheezing is often present, especially during exacerbations.
Diagnosis
- Spirometry:
- Diagnostic tool for COPD, showing:
- FEV1/FVC Ratio <0.70: Confirms airflow limitation after bronchodilator administration.
- Decreased FEV1: Reflects the severity of obstruction.
- Chest X-ray Findings:
- In advanced disease, hyperinflation, flattened diaphragms, and increased lung radiolucency may be seen.
Management
- Smoking Cessation:
- Most important intervention to slow disease progression.
- Bronchodilators:
- Short-acting beta agonists (SABAs): Used for symptom relief.
- Long-acting beta agonists (LABAs) and long-acting muscarinic antagonists (LAMAs): Maintenance therapies to improve lung function and reduce symptoms.
- Inhaled Corticosteroids (ICS):
- May be added to bronchodilators for patients with frequent exacerbations.
- Pulmonary Rehabilitation:
- Exercise training and education programs that improve physical conditioning and quality of life.
Exacerbations
- Definition:
- Sudden worsening of respiratory symptoms that requires additional treatment.
- Management:
- Bronchodilators: SABAs with or without short-acting anticholinergics.
- Corticosteroids: Short courses of oral prednisone (e.g., 40 mg for 5 days).
- Antibiotics: Indicated if purulent sputum or signs of infection are present.
Complications
- Pulmonary Hypertension:
- Results from chronic hypoxia, leading to right heart failure (cor pulmonale).
- Acute Respiratory Failure:
- Severe exacerbations can cause respiratory failure, requiring mechanical ventilation.
Key Points
- COPD is caused by chronic inflammation and parenchymal destruction, primarily due to smoking.
- The disease involves small airway obstruction and emphysema, with progressive airflow limitation confirmed by spirometry (FEV1/FVC ratio <0.70).
- Smoking cessation is the most effective intervention to halt disease progression.
- Bronchodilators and inhaled corticosteroids form the basis of pharmacologic treatment.
- Exacerbations, often triggered by infections, are managed with bronchodilators, corticosteroids, and antibiotics.
- Complications include pulmonary hypertension and respiratory failure.